A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects

Inclusion Criteria: * Normal healthy adult male or female subjects age greater than or equal to 18 years and less than or equal to 55 years old. * Body mass index greater than or equal to 18 kg/m2 and less than or equal to 32 kg/m2 at the time of screening. * Platelet count between 120x109/L and 250x109/L. * Women of childbearing potential must agree to use a double barrier method of contraception during the Randomization Phase of the study. Exclusion Criteria: * Evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal, respiratory, endocrine, hematologic, neurologic, or psychiatric disease or abnormalities or a known history of any gastrointestinal surgery that could impact the pharmacokinetics (PK)of the study drug. * Agents associated with thrombotic events (including oral contraceptives) must be discontinued within 30 days of the first study drug administration. * Evidence of organ dysfunction or any clinically significant deviation from normal in their medical history, e.g., history of splenectomy. * History of venous or arterial thrombotic disease or other hypercoaguable state. * Hemoglobin level less than 11.5 g/dL for females and 13.5g /dL for males